ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • lymph node and positron emission tomography (PET)
  • lymph node and rheumatoid arthritis
  • lymph node and rheumatoid arthritis (RA)
  • Lymph node and systemic lupus erythematosus (SLE)
  • lymph node and tertiary
  • lymphocyte and SLE
  • lymphocyte subsets
  • lymphocytes
  • lymphocytes and Effective
  • Lymphocytes and methotrexate (MTX)
  • lymphocytes and mitochondria
  • lymphocytes and natural killer (NK) cells
  • lymphocytes and pathogenesis
  • lymphocytes and psoriatic arthritis
  • lymphocytes and rheumatoid arthritis
  • lymphocytes and rheumatoid arthritis (RA)
  • lymphocytes and salivary gland
  • lymphocytes and scleroderma
  • lymphocytes and synovial fluid
  • lymphocytes and systemic lupus erythematosus (SLE)
  • lymphocytes and systemic sclerosis
  • Lymphocyturia
  • Lymphoid Aggregates
  • lymphoma
  • lymphopenia
  • lymphopenia and systemic lupus erythematosus (SLE)
  • lymphoproliferative disorders (LPD) and PMDA
  • Lyn
  • Lysosomal acidification and Immune complex accumulation
  • Lysosomal Storage Disorder
  • M-DAS
  • M3 muscarinic avetylcoline receptor
  • MAA
  • mab
  • MACE
  • machine learning
  • machine learning and deep learning
  • Macrophage
  • macrophage activation syndrome
  • macrophage activation syndrome and macrophages
  • macrophage activation syndrome and monoclonal antibodies
  • macrophage activation syndrome and monocytes
  • macrophage activation syndrome and mouse model
  • macrophage activation syndrome and multiorgan failure
  • macrophage activation syndrome and natural killer (NK) cells
  • macrophage activation syndrome and neutrophils
  • macrophage activation syndrome and nod-like receptor (NLR)
  • macrophage activation syndrome and pulmonary complications
  • macrophage activation syndrome and rheumatic disease
  • macrophage activation syndrome and risk
  • Macrophage activation syndrome and systemic lupus erythematosus (SLE)
  • macrophage activation syndrome and therapy
  • macrophage activation syndrome and tocilizumab
  • macrophage activation syndrome and toll-like receptors
  • Macrophage activation syndrome and treatment
  • macrophage activation syndrome and tuberculosis
  • macrophage activation syndrome and viruses
  • Macrophage and apoptotic clearance
  • Macrophage and arthritis
  • Macrophage and cutaneous lupus erythematosus
  • Macrophage and inflammation
  • Macrophage and lupus nephritis
  • Macrophage and methotrexate (MTX)
  • Macrophage and MicroRNA
  • Macrophage and monocytes
  • Macrophage and reactive arthritis
  • Macrophage and rheumatoid arthritis (RA)
  • Macrophage and systemic sclerosis
  • Macrophage migration inhibitory factor (MIF)
  • macrophage migration inhibitory factor (MIF) and monocytes
  • macrophage migration inhibitory factor (MIF) and rheumatoid arthritis (RA)
  • macrophage migration inhibitory factor (MIF) and systemic lupus erythematosus (SLE)
  • macrophage polarization
  • macrophages
  • macrophages and monocytes
  • macrophages and nephrogenic fibrosing dermopathy
  • macrophages and osteomyelitis
  • macrophages and pathogenesis
  • macrophages and phenotypes
  • macrophages and polymyalgia rheumatica
  • macrophages and rheumatoid arthritis
  • macrophages and rheumatoid arthritis (RA)
  • macrophages and signal transduction
  • macrophages and spondylarthritis
  • macrophages and spondylarthropathy
  • macrophages and systemic lupus erythematosus (SLE)
  • macrophages and systemic sclerosis
  • macrophages and tofacitinib
  • macrophages and toll-like receptors
  • macrophages and transcription factor
  • macrophages and treatment
  • macrophages and uric acid
  • Macrophages and vasculitis
  • Magnetic resonance imaging (MRI)
  • magnetic resonance imaging (MRI) and ankylosing spondylitis (AS)
  • magnetic resonance imaging (MRI) and cartilage
  • magnetic resonance imaging (MRI) and computed tomography (CT)
  • magnetic resonance imaging (MRI) and diagnosis
  • magnetic resonance imaging (MRI) and diagnostic imaging
  • magnetic resonance imaging (MRI) and Early Rheumatoid Arthritis
  • magnetic resonance imaging (MRI) and evaluation
  • magnetic resonance imaging (MRI) and Joint replacement
  • magnetic resonance imaging (MRI) and knee pain
  • magnetic resonance imaging (MRI) and Mimickers
  • magnetic resonance imaging (MRI) and myocardial involvement
  • magnetic resonance imaging (MRI) and myositis
  • magnetic resonance imaging (MRI) and nervous system lupus
  • magnetic resonance imaging (MRI) and neuroimaging
  • magnetic resonance imaging (MRI) and neurologic involvement
  • magnetic resonance imaging (MRI) and non-radiographic
  • magnetic resonance imaging (MRI) and osteoarthritis
  • magnetic resonance imaging (MRI) and outcome measures
  • magnetic resonance imaging (MRI) and pannus
  • magnetic resonance imaging (MRI) and pediatric rheumatology
  • magnetic resonance imaging (MRI) and pilot study
  • Magnetic resonance imaging (MRI) and polymyalgia rheumatica
  • magnetic resonance imaging (MRI) and polymyositis/dermatomyositis (PM/DM)
  • magnetic resonance imaging (MRI) and positron emission tomography (PET)
  • magnetic resonance imaging (MRI) and prognostic factors
  • magnetic resonance imaging (MRI) and psoriatic arthritis
  • magnetic resonance imaging (MRI) and qualitative
  • magnetic resonance imaging (MRI) and radiography
  • magnetic resonance imaging (MRI) and rheumatic disease
  • magnetic resonance imaging (MRI) and rheumatoid arthritis
  • magnetic resonance imaging (MRI) and rheumatoid arthritis (RA)
  • magnetic resonance imaging (MRI) and sacroiliac joints
  • magnetic resonance imaging (MRI) and scleroderma
  • Magnetic resonance imaging (MRI) and seronegative spondyloarthropathy
  • magnetic resonance imaging (MRI) and spondylarthritis
  • Magnetic resonance imaging (MRI) and spondylarthropathy
  • magnetic resonance imaging (MRI) and subchondral bone
  • magnetic resonance imaging (MRI) and synovitis
  • magnetic resonance imaging (MRI) and systemic lupus erythematosus (SLE)
  • Magnetic resonance imaging (MRI) and systemic sclerosis
  • magnetic resonance imaging (MRI) and takayasu arteritis
  • magnetic resonance imaging (MRI) and temporomandibular joint
  • magnetic resonance imaging (MRI) and tofacitinib
  • magnetic resonance imaging (MRI) and tracking
  • magnetic resonance imaging (MRI) and ultrasonography
  • magnetic resonance imaging (MRI) and ultrasound
  • magnetic resonance imaging (MRI) and vasculitis
  • magnetic resonance imaging (MRI) and x-ray
  • magnetic resonance imaging and osteoarthritis
  • Maintenance of certification
  • maintenance of certification and tacrolimus
  • maintenance therapy
  • MAIT cells and T cells
  • major adverse cardiovascular event
  • major histocompatibility complex (MHC)
  • major histocompatibility complex (MHC) and meta-analysis
  • major histocompatibility complex (MHC) and methylation
  • major histocompatibility complex (MHC) and nephritis
  • major histocompatibility complex (MHC) and population studies
  • Major histocompatibility complex (MHC) and psoriatic arthritis
  • major histocompatibility complex (MHC) and rheumatoid arthritis (RA)
  • major histocompatibility complex (MHC) and spondylarthritis
  • major histocompatibility complex (MHC) and systemic lupus erythematosus (SLE)
  • major histocompatibility complex (MHC) and systemic sclerosis
  • Malalignment
  • male and lower urinary tract symptom
  • male patient
  • Males with SLE
  • Malignancy
  • malignancy and drug toxicity
  • malignancy and health care cost
  • malignancy and lymphoma
  • malignancy and multicentric reticulohistiocytosis
  • malignancy and myositis
  • malignancy and pediatric rheumatology
  • malignancy and psoriatic arthritis
  • Malignancy and rheumatic disease
  • malignancy and rheumatoid arthritis
  • Malignancy and rheumatoid arthritis (RA)
  • Malignancy and risk
  • malignancy and sarcoidosis
  • malignancy and systemic lupus erythematosus
  • Malignancy and systemic lupus erythematosus (SLE)
  • malignancy and systemic sclerosis
  • Malignancy and tumor necrosis factor (TNF)
  • malignancy and vasculitis
  • MALT
  • MALT lymphoma
  • MALT lymphoma and salivary gland
  • Mammalian Target of Rapamycin (mTOR)
  • Managed Care
  • Managemenent
  • management
  • management and patient
  • management and patient outcomes
  • management and prognostic factors
  • management and psoriatic arthritis
  • management and registries
  • management and rheumatic disease
  • management and rheumatoid arthritis (RA)
  • management and rheumatologic practice
  • management and severity
  • management and systemic lupus erythematosus (SLE)
  • management and ultrasound
  • management and uveitis
  • management and vasculitis
  • First |
  • « Previous Page
  • 32
  • 33
  • 34
  • 35
  • 36
  • [37]
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology